European Commission approves Enhertu for residual HER2-positive early breast cancer after neoadjuvant therapynuaxiavor 5 Tagen2 Min. Lesezeit
FDA grants accelerated approval to Johnson & Johnson's Rybrevant Faspro for advanced head and neck cancer
